Study participants
Pustular Psoriasis, Psoriasis, fatigue, chronic illness, psoriasis
PSORIASIS, CHRONIC ILLNESS, PSORIASIS, GENERALIZED PUSTULAR PSORIASIS, PLAQUE PSORIASIS
In total, 29 Asian patients were enrolled and randomized in the Effisayil™ 1 study, of whom 16 were randomized to spesolimab and 13 to placebo (Table Baseline demographic and clinical characteristics of Asian patients in the Effisayil™ 1 studyAbbreviations: BMI, body mass index; CRP, C‐reactive protein; DLQI, dermatology quality of life index; FACIT‐Fatigue, functional assessment of chronic illness therapy–fatigue; GPP, generalized pustular psoriasis; GPPASI, Generalized Pustular Psoriasis Area and Severity Index; GPPGA, Generalized Pustular Psoriasis Physician Global Assessment; ICU, intensive care unit; JDA‐GPPSI, Japanese Dermatological Association Generalized Pustular Psoriasis Severity Index; PRO, patient‐reported outcome; PSS, psoriasis symptom scale; Q, quartile; SD, standard deviation; ULN, upper limit of normal; VAS, visual analog scale; WBC, white blood cell.Data are missing for one participant in the spesolimab group.‘Present or past psoriasis’ could encompass any type of psoriasis including plaque psoriasis, while ‘ongoing plaque psoriasis’ refers exclusively to plaque psoriasis.Data are missing for one participant in the placebo group.DNA sequencing was not performed in three participants in the spesolimab group and one in the placebo group.Data are missing for one participant in the spesolimab group and one in the placebo group.

Patient disposition. *Cyclosporine, betamethasone butyrate propionate (In the spesolimab group, four patients received an open‐label dose of spesolimab at Day 8 for persistent flare symptoms; of these, one patient received additional spesolimab after Day 8 (at Day 58) for a new flare. In the placebo group, 10 patients received an open‐label dose of spesolimab at Day 8 for persistent flare symptoms; two of these patients received additional spesolimab after Day 8 (at Days 44 and 68, respectively) for a new flare.